[go: up one dir, main page]

WO2018047013A8 - Formulations de 4-méthyl-5-(pyrazine-2-yl)-3 h-1,2-dithiole-3-thione, et leurs procédés de fabrication et d'utilisation - Google Patents

Formulations de 4-méthyl-5-(pyrazine-2-yl)-3 h-1,2-dithiole-3-thione, et leurs procédés de fabrication et d'utilisation Download PDF

Info

Publication number
WO2018047013A8
WO2018047013A8 PCT/IB2017/001312 IB2017001312W WO2018047013A8 WO 2018047013 A8 WO2018047013 A8 WO 2018047013A8 IB 2017001312 W IB2017001312 W IB 2017001312W WO 2018047013 A8 WO2018047013 A8 WO 2018047013A8
Authority
WO
WIPO (PCT)
Prior art keywords
making
dithiole
thione
pyrazin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/001312
Other languages
English (en)
Other versions
WO2018047013A1 (fr
Inventor
Anthony Chris GARLAND
Barbara-jean Anne BORMANN-KENNEDY
Bomi FRAMROZE
Bret Berner
Michael Edward GRASS
Casey Keith JAGER
Corey Jay Bloom
Mark Joseph KASTANTIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST IP Holding AG
Original Assignee
ST IP Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST IP Holding AG filed Critical ST IP Holding AG
Priority to AU2017323504A priority Critical patent/AU2017323504A1/en
Priority to JP2019535993A priority patent/JP2019531344A/ja
Priority to CN201780069787.9A priority patent/CN109996562A/zh
Priority to EP17808567.6A priority patent/EP3509642A1/fr
Priority to KR1020197010583A priority patent/KR102658015B1/ko
Publication of WO2018047013A1 publication Critical patent/WO2018047013A1/fr
Publication of WO2018047013A8 publication Critical patent/WO2018047013A8/fr
Priority to US16/351,058 priority patent/US11426403B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne, entre autres, des compositions comprenant des quantités de cristaux d'oltipraz, ainsi que des procédés de fabrication de telles compositions, et un procédé permettant de traiter des patients à l'aide de telles compositions.
PCT/IB2017/001312 2016-09-12 2017-09-12 Formulations de 4-méthyl-5-(pyrazine-2-yl)-3 h-1,2-dithiole-3-thione, et leurs procédés de fabrication et d'utilisation Ceased WO2018047013A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2017323504A AU2017323504A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
JP2019535993A JP2019531344A (ja) 2016-09-12 2017-09-12 ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法
CN201780069787.9A CN109996562A (zh) 2016-09-12 2017-09-12 4-甲基-5-(吡嗪-2-基)-3h-1,2-二硫杂环戊烯-3-硫酮的制剂及其制备和使用方法
EP17808567.6A EP3509642A1 (fr) 2016-09-12 2017-09-12 Formulations de 4-méthyl-5-(pyrazine-2-yl)-3 h-1,2-dithiole-3-thione, et leurs procédés de fabrication et d'utilisation
KR1020197010583A KR102658015B1 (ko) 2016-09-12 2017-09-12 4-메틸-5-(피라진-2-일)-3h-1,2-디티올-3-티온의 제제, 및 그의 제조 및 사용 방법
US16/351,058 US11426403B2 (en) 2016-09-12 2019-03-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201611031045 2016-09-12
US201662412681P 2016-10-25 2016-10-25
US62/412,681 2016-10-25
IN201611031045 2016-12-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/351,058 Continuation US11426403B2 (en) 2016-09-12 2019-03-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same

Publications (2)

Publication Number Publication Date
WO2018047013A1 WO2018047013A1 (fr) 2018-03-15
WO2018047013A8 true WO2018047013A8 (fr) 2018-05-24

Family

ID=61562532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/001312 Ceased WO2018047013A1 (fr) 2016-09-12 2017-09-12 Formulations de 4-méthyl-5-(pyrazine-2-yl)-3 h-1,2-dithiole-3-thione, et leurs procédés de fabrication et d'utilisation

Country Status (1)

Country Link
WO (1) WO2018047013A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019171174A2 (fr) * 2018-03-07 2019-09-12 St Ip Holding Ag Compositions et thérapies combinées comprenant de la 4-méthyl-5-(pyrazin-2-yl) -3h -1,2-dithiole-3-thione, et procédés de fabrication et d'utilisation associés
SG11202102653WA (en) * 2018-09-18 2021-04-29 St Ip Holding Ag Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones
CN111068058A (zh) * 2020-01-15 2020-04-28 云南中医药大学 PGC-1α激活剂在制备治疗脓毒症药物中的应用
TW202200144A (zh) 2020-03-16 2022-01-01 瑞士商Ｓｔ知識產權控股公司 ４—烷基—５—雜芳基—３ｈ—１，２—二硫雜環戊二烯—３—硫酮之旋轉異構異構物
US11135220B1 (en) * 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3156369A (en) 1962-09-19 1964-11-10 Ethicon Inc Bicameral container
NL171985C (nl) 1976-02-10 1983-06-16 Rhone Poulenc Ind Werkwijze voor het bereiden van preparaten met werking tegen schistosomiasis, de aldus verkregen gevormde preparaten en werkwijze voor het bereiden van 1,2-dithioolverbindingen.
IT1292677B1 (it) 1997-02-28 1999-02-11 Bormioli Metalplast Spa Confezione per mantenere separati dei prodotti prima dell'uso.
AU2001259484A1 (en) 2000-05-05 2001-11-20 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
KR100491318B1 (ko) * 2002-11-26 2005-05-24 씨제이 주식회사 올티프라즈(Ｏｌｔｉｐｒａｚ) 제조방법
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
CA2608978A1 (fr) 2005-07-15 2007-01-25 Bormioli Rocco & Figlio S.P.A. Reservoir dote d'un dispositif de coupe destine a des substances se melangeant a des liquides au moment de l'utilisation, reservoir destine en particulier a des recipients a dose unique
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
SI2536412T1 (sl) 2010-02-16 2015-05-29 Teva Branded Pharmaceutical Products R & D, Inc. Inhalabilen farmacevtski sestavek
CA2835293C (fr) * 2011-06-08 2020-08-18 Sti Pharma, Llc Preparation organique pharmaceutique hydrosoluble a absorption controlee administree une fois par jour
EP2757887B1 (fr) * 2011-09-22 2017-04-26 VIIV Healthcare UK Limited Composés pyrrolopyridinones et méthodes de traitement du vih
NZ629438A (en) 2012-02-28 2016-10-28 Iceutica Holdings Inc Inhalable pharmaceutical compositions
KR20160003183A (ko) 2013-04-29 2016-01-08 사노피 에스에이 흡입식 약학적 조성물 및 그를 포함하는 흡입기 장치
WO2016207914A2 (fr) 2015-06-25 2016-12-29 St Ip Holding Ag Procédé de préparation d'oltipraz

Also Published As

Publication number Publication date
WO2018047013A1 (fr) 2018-03-15

Similar Documents

Publication Publication Date Title
EP3898797A4 (fr) Compositions d'agent d'expansion contenant du 1,2,2-trifluoro-1-trifluorométhylcyclobutane, et procédés d'expansion
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
WO2018047013A8 (fr) Formulations de 4-méthyl-5-(pyrazine-2-yl)-3 h-1,2-dithiole-3-thione, et leurs procédés de fabrication et d'utilisation
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2020010369A (es) Particulas implantables y metodos relacionados.
EP3672973A4 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinase, compositions comprenant le composé hétérocyclique, et leurs procédés d'utilisation
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
EP3976595A4 (fr) Composés de 1-oxo-isoindoline-5-carboxamide substitués, compositions de ceux-ci, et procédés de traitement associés
EP4385521A3 (fr) Compositions stables au stockage et procédés de traitement d'erreurs de réfraction de l' il
PH12015502792A1 (en) Crystalline bromodomain inhibitors
EP4427808A3 (fr) Compositions et procédés pour réduire la néovascularisation oculaire
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
WO2017083431A3 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
EP3279207A4 (fr) Nouveau composé de 4'-thionucléoside, ainsi que son procédé de préparation, composition pharmaceutique comprenant celui-ci et son application
EP3697791A4 (fr) Composés hétérocycliques, compositions comprenant le composé hétérocyclique, et leurs procédés d'utilisation
ZA201807446B (en) Improved drug formulations
EP3176163A4 (fr) Nouveau derive d'indene, son procede de preparation, et composition pharmaceutique pour la prevention ou le traitement de maladies retiniennes en contenant comme principe actif
IL272767A (en) A preparation containing Wharton gel, a method for its preparation and its uses
MX2024010625A (es) Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.
WO2019171174A3 (fr) Compositions et thérapies combinées comprenant de la 4-méthyl-5-(pyrazin-2-yl) -3h -1,2-dithiole-3-thione, et procédés de fabrication et d'utilisation associés
PH12019500530A1 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
AU2017323504A8 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1, 2-dithiole-3-thione, and methods of making and using same
CA3003108A1 (fr) Composition stable au stockage comprenant de la rifaximine alpha

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17808567

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2019535993

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 20197010583

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2017323504

Country of ref document: AU

Date of ref document: 20170912

Kind code of ref document: A

ENP Entry into the national phase in:

Ref document number: 2017808567

Country of ref document: EP

Effective date: 20190412